Attached files
file | filename |
---|---|
8-K - 8-K - Cardiff Oncology, Inc. | a15-1372_18k.htm |
Exhibit 99.1
|
Trovagene to Present at the 7th Annual Biotech Showcase Conference
SAN DIEGO January 7, 2015 Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today announced that Chief Executive Officer Antonius Schuh, Ph.D. will provide an update on the Companys progress at the Biotech Showcase 2015 conference at 9:30 a.m. PST on Monday, January 12, 2015. The presentation will take place in D track Powell room at the Parc 55 Wyndam Hotel in San Francisco. Schuh will be available for one-on-one meetings during the conference, and a copy of the presentation will be available on Trovagenes Investor Relations page at http://trovagene.investorroom.com/overview.
About Trovagene, Inc.
Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The Companys technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagenes Precision Cancer MonitoringSM platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.
Trovagene Contacts
Investor Relations |
|
Media Relations |
David Moskowitz and Amy Caterina |
|
Ian Stone |
Investor Relations |
|
Account Director |
Trovagene, Inc. |
|
Canale Communications, Inc. |
858-952-7593 |
|
619-849-5388 |
ir@trovagene.com |
|
ian@canalecomm.com |
###
Trovagene Inc. | 11055 Flintkote Avenue | San Diego | CA 92121 | Tel.: USA [+1] 888-391-7992